Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA To Sponsors: No Dice On Appealing Advice Through Dispute Resolution

Executive Summary

Appeals pathway remains unavailable for challenging regulatory advice on drug and biologic product development programs despite objections from industry; sponsors may approach a higher management level to further discuss such advice in meetings established under the user fee programs, final guidance states.

Advertisement

Related Content

PTC To Appeal Translarna's Complete Response Letter From US FDA
Exondys Revisited? Translarna Brings Efficacy Woes Into US Panel Review
FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval
Dispute Resolution Strategies: FDA Clarifies Which Issues Can Be Appealed
If At First You Don’t Succeed, Try Dispute Resolution

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel